USSTOCK.TODAY
Market Closed
Log in Sign up

Alzamend Neuro Inc(ALZN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

ALZN
ALZN
Alzamend Neuro Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.02
-0.02 ▼ -1.92%
Nov 19 at 6:57 PM ET (Korea 11/20 08:57)
$1.13
+0.11 ▲ +10.78%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -2.29Insider Own ⓘ 2.66%Shs Outstand ⓘ 4.8MPerf Week ⓘ -21.54%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ 17.14%Insider Trans ⓘ -1.54%Shs Float ⓘ 4.7MPerf Month ⓘ -18.4%
Enterprise Value ⓘ -0.00BPEG ⓘ -EPS next Q ⓘ -0.23Inst Own ⓘ 28.24%Short Float ⓘ 0.37%Perf Quarter ⓘ -34.62%
Income ⓘ -0.01BP/S ⓘ -EPS this Y ⓘ 60.08%Inst Trans ⓘ -4.77%Short Ratio ⓘ 0.22Perf Half Y ⓘ -12.82%
Sales ⓘ 0.00BP/B ⓘ 0.85EPS next 5Y ⓘ -ROA ⓘ -122.36%Short Interest ⓘ 0.02MPerf YTD ⓘ -43.96%
Book/sh ⓘ 1.2P/C ⓘ 0.65EPS past 3/5Y ⓘ 76.63% 51.15%ROE ⓘ -163.23%52W High ⓘ -60.16% ($2.56)Perf Year ⓘ -55.84%
Cash/sh ⓘ 1.57P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -156.77%52W Low ⓘ 21.43% ($0.84)Perf 3Y ⓘ -99.33%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 73.61%Gross Margin ⓘ -Volatility(W/M) ⓘ 13.48% 12.4%Perf 5Y ⓘ -99.97%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.14Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 3.01EPS Q/Q ⓘ 47.33%Profit Margin ⓘ -RSI (14) ⓘ 30.51Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 3.01Sales Q/Q ⓘ -SMA20 ⓘ -19.08% ($1.26)Beta ⓘ 0.44Target Price ⓘ $26
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ 2026/09/15SMA50 ⓘ -29.04% ($1.44)Rel Volume ⓘ 0.47Prev Close ⓘ $1.04
Employees ⓘ 6LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ -SMA200 ⓘ -27.75% ($1.41)Avg Volume(3M) ⓘ 0.08MPrice ⓘ $1.02
IPO ⓘ 2021/6/15Option/Short ⓘ No/YesTrades ⓘ 323Volume ⓘ 37,518Change ⓘ -1.92%
Company
ALZN ALZNAlzamend Neuro Inc | NASD | Biotechnology Deep dive

🧠 This is a US micro-cap clinical-stage biotech developing therapeutics for brain and neurological disorders such as Alzheimer's disease, bipolar disorder, depression, and post-traumatic stress disorder (PTSD). Its key candidates are AL001, which delivers lithium in a novel crystalline form, and ALZN002, an immunotherapy targeting beta-amyloid.

Quote

Over the past 1 year, on the lower side

60% below its 1-year high.

Now $1.02
52w low$0.8452w high$2.56
52W Range10%
Volume ⓘ 37,518

Traded less than usual. That is 47% of its average volume.

C
Overall · average, with some caution
We judged 6 of the 8 questions below. 1 rate excellent and 3 need caution.
No data for valuation, dividends, or not applicable.
ETFs holding this stock 1 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #540 of 598 in the industry

Based on market cap of $5M.

FAQ

FAQ

What kind of company is ALZN?

ALZN belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ALZN?

The market cap of ALZN is approximately $5M, ranking 5,568 within its sector.

What is the 52-week high and low for ALZN?

ALZN has recorded a 52-week high of $2.56 and a low of $0.84.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels